Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Rezolute shares plunge after Phase 3 sunRIZE study fails to show significant benefit in congenital hyperinsulinism Rezolute shares collapsed after its Phase 3 sunRIZE trial failed in congenital hyperinsulinism. Find out what went wrong and what it means for investors now. bySoujanya RaviDecember 13, 2025